Medical device company Boston Scientific (NYSE: BSX) has agreed to purchase Symetis, a Swiss developer of devices used to perform heart surgery through blood vessels, for $435 million in up-front cash. This deal marks as Boston Scientific’s second acquisition in four months.
Symetis develops minimally invasive heart valve replacement devices out of its headquarters in Ecublens, Switzerland. The target’s product portfolio consists of Acurate TA and Acurate neo TF for use in the treatment of high-risk patients suffering from severe and symptomatic aortic valve stenosis. Symetis’ products are sold in Europe and in other regions outside of the United States.